selectION Announces Positive Results from Phase 1b Clinical Trial Evaluating si-544 in Patients with Atopic Dermatitis
29 avr. 2024 04h00 HE
|
AKAMPION
si-544 was well tolerated with no serious adverse effects, dose limiting toxicities, or safety signals observed75% of patients receiving si-544 experienced objective clinical improvement, of which 44%...
Sitryx nominates SYX-5219 a novel, oral and targeted PKM2 activator for clinical development in atopic dermatitis
10 avr. 2024 07h00 HE
|
Sitryx Therapeutics
Sitryx nominates SYX-5219 a novel, oral and targeted PKM2 activator for clinical development in atopic dermatitis First program from proprietary pipeline of novel immunometabolism-targeting therapies...
Atopic Dermatitis Market To Reach USD 18.6 Billion By 2032 Report By DataHorizzon Research
14 mars 2024 20h30 HE
|
DataHorizzon Research
Fort Collins, Colorado, March 14, 2024 (GLOBE NEWSWIRE) -- The Atopic Dermatitis Market size was valued at USD 9.1 Billion in 2023 and is expected to reach a market size of USD 18.6 Billion by 2032...
Dermatology Imaging Devices Market Report 2024, with Profiles of FotoFinder, e-con, Longport, Cortex Technology, VisualSonics, Clarius, Koninklijke Philips, Caliber Imaging and Diagnosis & DermLite
12 mars 2024 13h44 HE
|
Research and Markets
Dublin, March 12, 2024 (GLOBE NEWSWIRE) -- The "Dermatology Imaging Devices Market Size, Share & Trends Analysis Report By Modality (Digital Photographic Imaging, OCT, Dermatoscope, High...
Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting
10 mars 2024 16h00 HE
|
Arcutis Biotherapeutics, Inc.
Investigational roflumilast cream 0.05% met the primary endpoint and all secondary endpoints, showing significant improvement
Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting
04 mars 2024 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced five presentations at the 2024 American Academy of Dermatology (AAD) annual meeting.
Derm-Biome Pharmaceuticals prepares to begin IND-enabling studies for DB-007-4, a potential best-in-class treatment for inflammatory skin diseases
27 févr. 2024 10h00 HE
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals Inc, a Vancouver-based biopharmaceutical company developing novel topical therapies for inflammatory skin...
Dermatitis Global Market Report 2024: Analysis Reveals Key Trends in Biologics and Personalized Medicine Approaches - Long-term Forecasts to 2028 and 2033
26 janv. 2024 03h32 HE
|
Research and Markets
Dublin, Jan. 26, 2024 (GLOBE NEWSWIRE) -- The "Dermatitis Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. There is significant growth underway in the global...
Majority of Individuals with Atopic Dermatitis Improved with Arcutis’ Roflumilast Cream 0.15% According to New Data from Phase 3 Program
14 janv. 2024 04h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced new individual patient response data in Atopic Dermatitis with roflumilast cream according to new data from Phase 3 program
selectION, Inc. to Present Update on Clinical Progress at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on January 11, 2024
05 janv. 2024 04h00 HE
|
AKAMPION
Best-in-class Kv1.3 blocker has successfully completed a Phase 1b trial in atopic dermatitis patientsPipeline molecule to treat T cell mediated autoimmune diseases San Diego, CA, USA, and...